Glabellar (Frown) Lines – A
In the largest aesthetic neuromodulator clinical trial ever conducted for the treatment of glabellar frown lines, our lead compound DaxibotulinumtoxinA for Injection delivered unprecedented duration and efficacy of effect.
DaxibotulinumtoxinA for Injection has the potential to deliver the first long-lasting injectable formulation of botulinum toxin type A, representing the first major innovation to hit the $4.5 billion neuromodulator market in 30 years.
DaxibotulinumtoxinA for Injection has been evaluated in a Phase 2 head-to-head, active comparator study (BELMONT), and in three Phase 3 trials (SAKURA 1, 2, 3) for the treatment of glabellar lines. We plan to file for regulatory approval in 2019 and potentially launch DaxibotulinumtoxinA for Injection in 2020.
Forehead Lines and Lateral Canthal Lines (Crow’s Feet) – B&C
DaxibotulinumtoxinA for Injection is also being studied for the treatment of forehead lines and lateral canthal lines, commonly known as crow’s feet. Phase 2 trials are expected to be fully enrolled in the Summer of 2019 and have results in the first half of 2020. For the latest information regarding our clinical development programs, please see our public filings with the Securities and Exchange Commission or visit clinicaltrials.gov.